Promising Therapy Options for Controlling High Grade Risk of Non-Muscle Invasive Bladder Cancer Patients

Promising Therapy Options for Controlling High Grade Risk of Non-Muscle Invasive Bladder Cancer Patients

Release Date: 03-Nov-2020



It has been well observed that the high risk of cancer recurrence is based on the disease state in case of non-muscle invasive bladder cancer. Also, BCG has remained standard of care for these patients as there are scarcity of effective treatments for such diseases.  The researchers working on such paradigm defined the risk strata of the non-muscle invasive bladder cancer such as number of tumors, size, recurrences, stage (T category), concomitant carcinoma in situ, and grade with the help of European Organization for Research and Treatment of Cancer (EORTC) risk calculator.

 

Multiple efforts have been put to reduce the burden that is associated with BCG such as decrease in dose frequency and dose reductions. The risk calculator demonstrated that the probability of cancer recurrence compared with the standard therapy arm of the NIMBUS trial as well as CUETO risk calculator also over-estimated the probability of recurrence, at least among high-risk individuals.

 

As per research analysis, the patients receiving BCG unresponsive disease as well as guidelines recommend radical cystectomy with bladder preservation strategies, preferably within the context of clinical trials can be offered to the patients who have refused cystectomy.  Following were the observed results: 40.6% complete response rate, 6% recurrent disease, 9% median duration of response, 42% persistent disease and no progression to muscle invasive disease in the single arm trial (KEYNOTE-057).

Need custom market research solution? We can help you with that too.